The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 603-608

  Zhaung, Hong Qing ^a   Bo, Qi Fu ^b   Yuan, Zhi Yong ^a   Wang, Jun ^a   Zhao, Lu Jun ^a   Wang, Ping ^a  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Erlotinb; PI3K; Radiosensitization effects; Tyrosine kinase inhibitor

Indexed keywords

ERLOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME POLYMORPHISM; ENZYME REGULATION; INTRACELLULAR SIGNALING; ONCOLOGICAL PARAMETERS; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; SENSITIZER ENHANCEMENT RATIO; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84879017500     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S44505     Document Type: Article

References (29)

1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4:361-370.
2. Baselga B. Epidermal growth factor receptor pathway inhibitors. Update Cancer Ther. 2006;1:299-310.
3. Ciariello F, Tortora G. EGFR Antagonists in Cancer Treatment. N Engl J Med. 2008;358(11):1160-1174.
4. Ciariello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7(10):2958-2970.
5. Zhu Z. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sin. 2007;28(9):1476-1493.
6. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11(4):689-708.
7. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol. 2007;62(1):53-61.
8. Kris MG, Natale RB, Herbst RS, et al. Efficacy of geftinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-2158.
9. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of geftinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237-2246.
10. Liu F, Li Y, Yu Y, Fu S, Li P. Cloning of novel tumor metastasis-related genes from the highly metastatic human lung adenocarcinoma cell line Anip973. J Genet Genomics. 2007;34(3):189-195.
11. Li W, Mu D, Song L, et al. Molecular mechanism of silymarin-induced apoptosis in a highly metastatic lung cancer cell line anip973. Cancer Biother Radiopharm. 2011;26(3):317-324.
12. Chu PM, Chiou SH, Su TL, et al. Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response. Radiat Oncol. 2011;6:7.
13. Cariveau MJ, Stackhouse M, Cui XL, et al. Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response. Int J Radiat Oncol Biol Phys. 2008;70(1):213-220.
14. Quanz M, Berthault N, Roulin C, et al. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. Clin Cancer Res. 2009;15(4):1308-1316.
15. Kim IA, Shin JH, Kim IH, et al. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential infuence of p53. Clin Cancer Res. 2006;12(3 Pt 1): 940-949.
16. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005;65(4):1479-1488.
17. Lind JS, Lagerwaard FJ, Smit E F, Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1391-1396.
18. Stinchcombe TE, Bogart JA. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist. 2012;17(5):682-693.
19. Merimsky O, Cheng CK, Au JS, von Pawel J, Reck M. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer. Oncol Rep. 2012;28(2):721-727.
20. Mehta VK. Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. Front Oncol. 2012;2:31.
21. Maines MD. Biliverdin reductase: PKC interaction at the cross-talk of MAPK and PI3K signaling pathways. Antioxid Redox Signal. 2007;9(12):2187-2195.
22. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fne balance. Biochem Soc Trans. 2012;40(1):139-146.
23. Menges C W, McCance DJ. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene. 2008;27(20): 2934-2940.
24. Jung KH, Park BH, Hong SS. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res. 2012;35(4):595-604.
25. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011;103(8):645-661.
26. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs. 2008;17(7): 997-1011.
27. Stea B, Falsey R, Kislin K. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett. 2003;202(1):43-51.
28. Andersson U, Johansson D, Behnam-Motlagh P, Johansson M, Malmer B. Treatment schedule is of importance when geftinib is combined with irradiation of glioma and endothelial cells in vitro. Acta Oncol. 2007;46(7):951-960.
29. Nanda A, Dias-Santagata DC, Stubbs H, et al. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin Lung Cancer. 2008;9(5):285-287.